WEST Search History

Hide Items | Restore | Clear | Cancel

DATE: Tuesday, May 17, 2005

Hide?	Set Name	Query	Hit Count
		DB=USPT; PLUR=YES; OP=ADJ	
☐	L34	L33 and rabies	1
☐	L33	6194560.pn.	1
☐	L32	5989561.pn. and rabies	1
☐	L31	5989561.pn.	1
☐	L30	L28 and protection	1
☐	L29	L28 and cross	1
☐	L28	5843456.pn.	1
☐	L27	5843356.pn.	1
☐	L26	herpesvirus cross recativity	0
		DB=PGPB; PLUR=YES; OP=ADJ	
☐	L25	herpesvirus cross recativity	0
☐	L24	herpesvirus cross protection	0
☐	L23	rabies cross protection	0
		DB=USPT; PLUR=YES; OP=ADJ	
☐	L22	rabies cross protection	0
		DB=DWPI; PLUR=YES; OP=ADJ	
☐	L21	rabies cross protection	0
☐	L20	rabies antigenic cross reactivity	0
		DB=USPT; PLUR=YES; OP=ADJ	
☐	L19	rabies antigenic cross reactivity	0
		DB=PGPB; PLUR=YES; OP=ADJ	
☐	L18	rabies antigenic cross reactivity	0
☐	L17	rabies antigenic cross activity	0
☐	L16	rabies overlapping activity	0
☐	L15	rabies cross reactivity	0
		DB=USPT; PLUR=YES; OP=ADJ	
☐	L14	rabies cross reactivity	0
		DB=DWPI; PLUR=YES; OP=ADJ	
☐	L13	rabies cross reactivity	0
☐	L12	rabies cross reactivity and herpesvirus	0
		DB=USPT; PLUR=YES; OP=ADJ	

☐	L11	US-4680176-A.did.	1
☐	L10	US-4680176-A.did.	1
	DB=DWPI; PLUR=YES; OP=ADJ		
☐	L9	rabies and herpesvirus	23
	DB=USPT; PLUR=YES; OP=ADJ		
☐	L8	rabies and herpesvirus.clm.	54
☐	L7	4584194.pn.	1
☐	L6	4351827.pn.	1
☐	L5	4341762.pn.	1
☐	L4	0206940.pn.	1
☐	L3	4657761.pn.	1
☐	L2	6174916.pn.	1
☐	L1	4415590.pn.	1

END OF SEARCH HISTORY

WEST Search History

Hide Items | Restore | Clear | Cancel

DATE: Tuesday, May 17, 2005

Hide?	Set Name	Query	Hit Count
		DB=USPT; PLUR=YES; OP=ADJ	
☐	L10	herpes cross reacting rabies	0
☐	L9	rabies cross reacting herpes	0
☐	L8	L6 and rabies	12
☐	L7	L6 and herpesvirus	9
☐	L6	beta propriolactone	112
		DB=JPAB; PLUR=YES; OP=ADJ	
☐	L5	IMOVAX	0
		DB=EPAB; PLUR=YES; OP=ADJ	
☐	L4	IMOVAX	0
		DB=DWPI; PLUR=YES; OP=ADJ	
☐	L3	IMOVAX	0
		DB=PGPB; PLUR=YES; OP=ADJ	
☐	L2	IMOVAX	3
		DB=USPT; PLUR=YES; OP=ADJ	
☐	L1	IMOVAX	5

END OF SEARCH HISTORY

TI Polynucleotide vaccine formula against canine pathologies
IN Audonnet, Jean-Christophe, Lyons, France
Bouchardon, Annabelle, Lyons, France
Riviere, Michel, Ecully, France
PA Merial, Lyons, France (non-U.S. corporation)
PI US 6228846 B1 20010508
AI US 1999-232477 19990115 (9)
RLI Continuation-in-part of Ser. No. WO 1997-FR1316, filed on 15 Jul 1997
PRAI FR 1996-9401 19960719
DT Utility
FS Granted
LN.CNT 888
INCL INCLM: 514/044.000
INCLS: 435/320.100; 536/023.720; 536/023.700
NCL NCLM: 514/044.000
NCLS: 435/320.100; 536/023.700; 536/023.720
IC [7]
ICM: A61K031-70
EXF 514/44; 424/233.1; 435/320.1; 435/23.7; 536/23.72
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 10 OF 13 USPATFULL on STN
AN 2001:29710 USPATFULL
TI Oral immunization with transgenic plants
IN Arntzen, Charles J., Ithaca, NY, United States
Mason, Hugh S., Ithaca, NY, United States
Haq, Tariq A., San Antonio, TX, United States
PA Texas A & M University System, College Station, TX, United States (U.S. corporation)
PI US 6194560 B1 20010227
AI US 1998-191852 19981112 (9)
RLI Division of Ser. No. US 817906, now abandoned Continuation-in-part of Ser. No. US 1994-328716, filed on 24 Oct 1994, now abandoned
DT Utility
FS Granted
LN.CNT 2819
INCL INCLM: 536/023.700
INCLS: 800/278.000; 800/288.000; 800/295.000; 530/350.000; 435/069.100; 435/069.300; 435/410.000; 435/419.000; 435/252.300; 435/252.330; 435/252.800; 435/320.100; 424/184.100; 424/185.100; 424/186.100; 424/190.100; 424/192.100; 424/193.100; 424/204.100; 424/227.100; 424/236.100; 424/241.100; 424/282.100; 536/023.100
NCL NCLM: 536/023.700
NCLS: 424/184.100; 424/185.100; 424/186.100; 424/190.100; 424/192.100; 424/193.100; 424/204.100; 424/227.100; 424/236.100; 424/241.100; 424/282.100; 435/069.100; 435/069.300; 435/252.300; 435/252.330; 435/252.800; 435/320.100; 435/410.000; 435/419.000; 530/350.000; 536/023.100; 800/278.000; 800/288.000; 800/295.000
IC [7]
ICM: A61K039-108
ICS: C07H021-04; C07K014-245; C12N005-14
EXF 536/23.1; 536/23.7; 800/278; 800/288; 800/295; 530/350; 435/69.1; 435/69.3; 435/410; 435/419; 435/252.3; 435/252.33; 435/252.8; 435/320.1; 424/184.1; 424/185.1; 424/186.1; 424/190.1; 424/192.1; 424/193.1; 424/204.1; 424/227.1; 424/236.1; 424/241.1; 424/282.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 11 OF 13 USPATFULL on STN
AN 1999:150664 USPATFULL
TI Recombinant poxvirus-calicivirus rabbit hemorrhagic disease virus (RHDV) compositions and uses
IN Paoletti, Enzo, Delmar, NY, United States
Fischer, Laurent, Albany, NY, United States
Legros, Francois-Xavier, Oullins, France
PA Virogenetics Corporation, Troy, NY, United States (U.S. corporation)
PI US 5989561 19991123
AI US 1995-471025 19950606 (8)
RLI Continuation-in-part of Ser. No. US 1993-105483, filed on 13 Aug 1993,

now patented, Pat. No. US 5494807 And Ser. No. US 1993-36217, filed on 24 Mar 1993, now patented, Pat. No. US 5364773, issued on 15 Nov 1994 which is a continuation of Ser. No. US 1991-666056, filed on 7 Mar 1991, now abandoned , said Ser. No. US 105483 which is a continuation of Ser. No. US 1992-847951, filed on 6 Mar 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-713967, filed on 11 Jun 1991, now abandoned which is a continuation-in-part of Ser. No. US 666056

DT Utility
FS Granted
LN.CNT 3738
INCL INCLM: 424/199.100
INCLS: 424/204.100; 435/235.100; 435/320.100; 435/325.000; 435/069.100; 536/024.310; 536/024.330; 536/023.720
NCL NCLM: 424/199.100
NCLS: 424/204.100; 435/069.100; 435/235.100; 435/320.100; 435/325.000; 536/023.720; 536/024.310; 536/024.330
IC [6]
ICM: A61K039-285
ICS: C12N015-80; C12N007-01
EXF 424/199.1; 424/204.1; 435/235.1; 435/320.1; 435/325; 435/69.1; 536/24.31; 536/23.72; 536/24.33
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 12 OF 13 USPATFULL on STN
AN 1999:72572 USPATFULL
TI DNA transcription unit vaccines that protect against avian influenza viruses and methods of use thereof
IN Webster, Robert, Memphis, TN, United States
PA St. Jude Children's Research Hospital, Memphis, TN, United States (U.S. corporation)
PI US 5916879 19990629
AI US 1996-747286 19961112 (8)
DT Utility
FS Granted
LN.CNT 1891
INCL INCLM: 514/044.000
INCLS: 435/459.000; 435/320.100; 536/023.720; 424/209.100; 424/210.100; 424/816.000
NCL NCLM: 514/044.000
NCLS: 424/209.100; 424/210.100; 424/816.000; 435/320.100; 435/459.000; 536/023.720
IC [6]
ICM: A61K048-00
ICS: C12N015-87; C12N015-44
EXF 536/23.72; 514/44; 424/209.1; 424/816; 424/199.1; 424/210.1; 435/320.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 13 OF 13 USPATFULL on STN
AN 1998:150475 USPATFULL
TI Alvac poxvirus-**rabies** compositions and combination compositions and uses
IN Paoletti, Enzo, Delmar, NY, United States
Maki, Joanne, Colbert, GA, United States
PA Virogenetics Corporation, Troy, NY, United States (U.S. corporation)
PI US 5843456 19981201
AI US 1995-486969 19950607 (8)
RLI Continuation-in-part of Ser. No. US 1993-105483, filed on 13 Aug 1993, now patented, Pat. No. US 5494807 which is a continuation of Ser. No. US 1992-847951, filed on 6 Mar 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-713967, filed on 11 Jun 1991, now abandoned which is a continuation-in-part of Ser. No. US 1991-666056, filed on 7 Mar 1991, now abandoned which is a continuation of Ser. No. US 1993-36217, filed on 24 Mar 1993, now patented, Pat. No. US 5364773, issued on 15 Nov 1994
DT Utility
FS Granted
LN.CNT 7179
INCL INCLM: 424/199.100

INCLS: 424/204.100; 424/201.100; 424/202.100; 424/205.100; 424/218.100;
424/224.100; 435/320.100; 435/069.300; 435/172.300; 435/235.100;
435/252.300; 530/350.000; 530/826.000; 514/002.000

NCL NCLM: 424/199.100

NCLS: 424/201.100; 424/202.100; 424/204.100; 424/205.100; 424/218.100;
424/224.100; 435/069.300; 435/235.100; 435/252.300; 435/320.100;
514/002.000; 530/350.000; 530/826.000

IC [6]

ICM: A61K039-275

ICS: A61K039-295; A61K039-205

=> d l9 1-64 ti

L9 ANSWER 1 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
TI Assessment of potency of canine vacines during thier shelf life.

L9 ANSWER 2 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
TI Molecular methods for diagnosis of viral encephalitis.

L9 ANSWER 3 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
TI Host-dependent type 1 cytokine responses driven by inactivated viruses may fail to default in the absence of IL-1 2 or IFN-alpha/beta.

L9 ANSWER 4 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
TI Human immunodeficiency virus transmitted through sheep brain anti-**rabies** vaccination.

L9 ANSWER 5 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
TI Bovine **herpesvirus** type 5 (BHV-5) in a calf with **rabies**

L9 ANSWER 6 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
TI Cerebellar loops pith motor cortex and prefrontal cortex of a nonhuman primate.

L9 ANSWER 7 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
TI Diagnostic immunohistochemistry of equine and avian infectious diseases.

L9 ANSWER 8 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
TI Infection as a cause of multiple sclerosis: Theories abound because no one knows the answers yet.

L9 ANSWER 9 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
TI Detection of bovine **herpesvirus** type 5 (BoHV-5) in cattle in Southeast Brazil.
Original Title: Deteccao de **herpesvirus** bovino 5 (BoHV-5) em bovinos do Sudeste Brasileiro.

L9 ANSWER 10 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
TI Interaction of the poliovirus receptor CD155 with the dynein light chain Tctex-1 and its implication for poliovirus pathogenesis.

L9 ANSWER 11 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
TI DNA immunization and central nervous system viral infection.

L9 ANSWER 12 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
TI Programmed cell death in virus infections of the nervous system.

L9 ANSWER 13 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
TI Canine **herpesvirus** based recombinant live vaccine, in particular against canine distemper, **rabies** or the parainfluenza 2 virus.

L9 ANSWER 14 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
TI Viral diseases of northern ungulates.

L9 ANSWER 15 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
TI Passive immunity in prevention and treatment of infectious diseases.

L9 ANSWER 16 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
TI Serologic survey of selected viral agents in recently captured wild North American river otters (Lontra canadensis).

L9 ANSWER 17 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
TI Diseases of the central nervous system in cattle of southern Brazil.

L9 ANSWER 18 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
TI Endogenous retroviruses: Are they the cause of multiple sclerosis?.

L9 ANSWER 19 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
TI New approaches to the development of virus vaccines for veterinary use.

L9 ANSWER 20 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
TI Construction of canine **herpesvirus** vector expressing foreign genes using a lacZ-TK gene cassette as a double selectional marker.

L9 ANSWER 21 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
TI Feline vaccine guidelines.

L9 ANSWER 22 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
TI Biological and immunogenic properties of **rabies** virus glycoprotein expressed by canine **herpesvirus** vector.

L9 ANSWER 23 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
TI Emerging viruses.

L9 ANSWER 24 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
TI Immunopathogenesis of virus diseases affecting the central nervous system.

L9 ANSWER 25 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
TI Protein-glycosaminoglycan interactions: Infectiological aspects.

L9 ANSWER 26 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
TI Viral encephalitides.

L9 ANSWER 27 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
TI Guidelines for vaccination of horses.

L9 ANSWER 28 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
TI Effects of incidental infections and immune activation on disease progression in experimentally feline immunodeficiency virus-infected cats.

L9 ANSWER 29 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
TI Resistance of mice vaccinated with **rabies** virus internal structural proteins to lethal infection.

L9 ANSWER 30 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
TI Diseases and parasites of red foxes, gray foxes, and coyotes from commercial sources selling to fox-chasing enclosures.

L9 ANSWER 31 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
TI PRINCIPLES AND PRACTICE OF CLINICAL VIROLOGY 2ND EDITION.

L9 ANSWER 32 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN

TI THERAPY OF VIRAL INFECTIONS OF THE CENTRAL NERVOUS SYSTEM.

L9 ANSWER 33 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
TI PENETRATION OF THE NERVOUS SYSTEM OF SUCKLING MICE BY MAMMALIAN REOVIRUSES.

L9 ANSWER 34 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
TI A CASE REPORT ENCEPHALITIS IN LIONS PATHOLOGICAL AND VIROLOGICAL FINDINGS.

L9 ANSWER 35 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
TI USE OF GENETIC ENGINEERING METHODS IN VIRAL VACCINE PRODUCTION.

L9 ANSWER 36 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
TI SEROLOGIC SURVEY OF VIRAL ANTIBODIES IN THE PERUVIAN ALPACA LAMA-PACOS.

L9 ANSWER 37 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
TI PERSISTENT VIRAL INFECTION THE CARRIER STATE.

L9 ANSWER 38 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
TI DIAGNOSIS OF FELINE VIRAL INFECTION.

L9 ANSWER 39 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
TI SLOW LATENT CHRONIC OR RECURRENT VIRAL INFECTIONS OF THE NERVOUS SYSTEM IN MAN.

L9 ANSWER 40 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
TI CELLULAR IMMUNITY IN **HERPESVIRUS** THAI HEMORRHAGIC FEVER AND OTHER CELLULAR INFECTIONS WITH EMPHASIS ON ISOPRINOSINE.

L9 ANSWER 41 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
TI VIRAL INFECTIONS OF THE NERVOUS SYSTEM.

L9 ANSWER 42 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
TI RAPID VIRUS DIAGNOSIS APPLICATION OF IMMUNO FLUORESCENCE 2ND EDITION.

L9 ANSWER 43 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
TI SEARCH FOR ANTI VIRAL AGENTS.

L9 ANSWER 44 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
TI PRIMARY SCREENING OF VIRAL INHIBITORS IN TISSUE CULTURE.

L9 ANSWER 45 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
TI INACTIVATION OF A TURKEY **HERPESVIRUS** BY UV LIGHT.

L9 ANSWER 46 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
TI CANINE AND FELINE IMMUNIZATION.

L9 ANSWER 47 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
TI THE COMPARISON OF VIRAL ANTIBODY TITERS OF ACID PRECIPITATED AND NONPRECIPITATED MOUSE ASCITIC FLUIDS.

L9 ANSWER 48 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN

TI INDUCTION OF INTERFERON IN-VIVO BY POLY NUCLEOTIDES.

L9 ANSWER 49 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
TI SENSITIVITY OF VARIOUS PRIMATE CELLS AND ANIMAL VIRUSES TO THE ANTI VIRAL ACTIVITY OF HUMAN LEUKOCYTE INTERFERON.

L9 ANSWER 50 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
TI ULTRASTRUCTURAL IDENTIFICATION OF VIRUS IN HUMAN CENTRAL NERVOUS SYSTEM DISEASE.

L9 ANSWER 51 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
TI CAUSES OF THE DEATH OF WILD UNGULATES IN THE CENTRAL DNIEPER REGION RUSSIAN-SFSR USSR.

L9 ANSWER 52 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
TI THE DETECTION OF TRANSMISSIBLE GASTROENTERITIS VIRAL ANTIBODIES BY IMMUNO DIFFUSION.

L9 ANSWER 53 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
TI VIRAL IMMUNO DIAGNOSIS.

L9 ANSWER 54 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
TI VIRAL ENCEPHALITIS A CLINICAL ELECTRO ENCEPHALOGRAPHIC VIROLOGICAL AND PATHOLOGICAL STUDY IN 32 CASES.

L9 ANSWER 55 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
TI COMPARATIVE STUDY OF THE PROTEIN KINASE ASSOCIATED WITH ANIMAL VIRUSES.

L9 ANSWER 56 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
TI CHANGES IN CENTRAL NERVOUS SYSTEM NEURONS IN WHITE MICE UNDER THE INFLUENCE OF SOME NEUROTROPIC VIRUSES.

L9 ANSWER 57 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
TI INHIBITORS AGAINST **RABIES** VIRUS PRESENT IN NORMAL RABBIT SERA.

L9 ANSWER 58 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
TI ZOONOSES OF LABORATORY ANIMALS VIRAL AND RICKETTSIAL.

L9 ANSWER 59 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
TI IMMUNO PATHOLOGY DURING VIRAL INFECTIONS.

L9 ANSWER 60 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
TI SOME FORMS OF VIRAL ZOONOSIS.

L9 ANSWER 61 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
TI ISOPRINOSINE LACK OF ANTI VIRAL ACTIVITY IN EXPERIMENTAL MODEL INFECTIONS.

L9 ANSWER 62 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
TI A COORDINATED STUDY OF THE ANTI VIRAL SUBSTANCE PROGRAM.

L9 ANSWER 63 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
TI IMMUNO SUPPRESSION AND EXPERIMENTAL VIRUS INFECTION OF THE NERVOUS SYSTEM.

L9 ANSWER 64 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
TI DIAGNOSTIC PROCEDURES FOR VIRAL AND RICKETTSIAL INFECTIONS.

=> d 19 29

L9 ANSWER 29 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
AN 1993:478535 BIOSIS
DN PREV199396112135
TI Resistance of mice vaccinated with **rabies** virus internal structural proteins to lethal infection.
AU Takita-Sonoda, Y.; Fujii, H.; Mifume, K. [Reprint author]; Ito, Y.; Hiraga, M.; Nishizona, A.; Mannen, K.; Minamoto, N.
CS Dep. Microbiol., Oita Med. Univ., Hasama-machi, Oita 879-55, Japan
SO Archives of Virology, (1993) Vol. 132, No. 1-2, pp. 51-65.
CODEN: ARVIDF. ISSN: 0304-8608.
DT Article
LA English
ED Entered STN: 22 Oct 1993
Last Updated on STN: 22 Oct 1993

=> d 19 29 ab

L9 ANSWER 29 OF 64 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
AB Mice were vaccinated with recombinant vaccinia virus (rVac) expressing the glycoprotein (G), nucleoprotein (N), phosphoprotein (NS) or matrix protein (M) of **rabies** virus and their resistance to peripheral lethal infection with street **rabies** virus was examined. Mice vaccinated with rVac-G or rVac-N developed strong antibody responses to the corresponding proteins and essentially all mice survived challenge infection. Mice vaccinated with rVac-NS or rVac-M developed only a slight antibody response, however, a significant protection (59%) was observed in the rVac-NS-vaccinated mice, whereas rVac-M-vaccinated mice were not protected. No anti-G antibodies were detected in the sera of mice which had been vaccinated with rVac-N or rVac-NS and survived challenge infection. Passive transfer of anti-N monoclonal antibodies (MAbs) recognizing an epitope located on amino acids 1-224 of the protein prior to challenge resulted in significant protection, although the protection was not complete even with a high amount of antibodies. In contrast, none of the mice given MAbs recognizing an epitope of amino acids 247-415 or F(ab')-2 fragments from a protective MAb IgG were protected. Administration of anti-CD8 MAb to rVac-N-vaccinated mice showed no significant effect on protection. Our observations suggest that a considerable part of the protection achieved by the vaccination with rVac-N can be ascribed to the intact anti-N antibodies recognizing an epitope located on amino acids 1-224 of the protein.

```
=> d his

     (FILE 'HOME' ENTERED AT 10:39:13 ON 17 MAY 2005)

     FILE 'MEDLINE' ENTERED AT 10:39:23 ON 17 MAY 2005
L1            49 S RABIES AND HERPESVIRUS
L2         19817 S CROSS REACTIV?
L3             0 S L1 AND L2
L4           802 S CROSS PROTECTION
L5             0 S L1 AND L4
L6             9 S L4 AND RABIES

     INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE,
     AQUASCI, BIOBUSINESS, BIOCOMMERCE, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS,
     BIOTECHNO, CABA, CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB,
     CROPU, DDFB, DDFU, DGENE, DISSABS, ...' ENTERED AT 10:47:35 ON 17 MAY 2005
               SEA L1 AND L4
              ---------
               1   FILE AGRICOLA
              13   FILE USPATFULL
               1   FILE USPAT2
               1   FILE VETU
L7             QUE L1 AND L4
              ---------

     FILE 'USPATFULL' ENTERED AT 10:50:46 ON 17 MAY 2005
L8            13 S L1 AND L4

     FILE 'BIOSIS' ENTERED AT 10:52:50 ON 17 MAY 2005
L9            64 S L1
```

```
=> d l8 1-13

L8   ANSWER 1 OF 13  USPATFULL on STN
AN     2005:62587  USPATFULL
TI     Anti-coronavirus vaccine
IN     Aubert, Andre, Antibes, FRANCE
       Duquesne, Veronique, Carros, FRANCE
       Eloit, Marc, Saint-Maur, FRANCE
       Gonon, Valerie, Le Perray en Yvelines, FRANCE
PI     US 2005053622      A1   20050310
AI     US 2004-485258     A1   20040810 (10)
       WO 2002-FR2843          20020809
PRAI   FR 2001-10644       20010809
DT     Utility
FS     APPLICATION
LN.CNT 1420
INCL   INCLM: 424/204.100
       INCLS: 530/350.000
NCL    NCLM:  424/204.100
       NCLS:  530/350.000
IC     [7]
       ICM: A61K039-12
       ICS: C07K014-005
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8   ANSWER 2 OF 13  USPATFULL on STN
AN     2004:150989  USPATFULL
TI     Imunogenic complex comprising ribosomes
IN     Timmerman, Benedikt, Toulouse, FRANCE
PI     US 2004115210      A1   20040617
AI     US 2003-250664     A1   20030707 (10)
       WO 2002-IB739           20020104
PRAI   GB 2001-757         20010106
DT     Utility
FS     APPLICATION
LN.CNT 2428
INCL   INCLM: 424/184.100
NCL    NCLM:  424/184.100
IC     [7]
       ICM: A61K039-00
       ICS: A61K039-38
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8   ANSWER 3 OF 13  USPATFULL on STN
AN     2004:50422  USPATFULL
TI     Vaccines for cat scratch fever
IN     Chomel, Bruno B., Davis, CA, UNITED STATES
       Kasten, Rickie W., Davis, CA, UNITED STATES
       Yamamoto, Kazuhiro, Yao-City, JAPAN
PA     REGENTS OF THE UNIVERSITY OF CALIFORNIA, Oakland, CA, 94607 (U.S.
       corporation)
PI     US 2004037849      A1   20040226
AI     US 2002-227078     A1   20020821 (10)
DT     Utility
FS     APPLICATION
LN.CNT 731
INCL   INCLM: 424/204.100
       INCLS: 435/252.100
NCL    NCLM:  424/204.100
       NCLS:  435/252.100
IC     [7]
       ICM: A61K039-12
       ICS: C12N001-20

L8   ANSWER 4 OF 13  USPATFULL on STN
AN     2003:194137  USPATFULL
TI     Polynucleotide vaccine formula against canine pathologies, in particular
```

respiratory and digestive pathologies
IN Audonnet, Jean-Christophe, Lyon, FRANCE
Bouchardon, Annabelle, Lyon, FRANCE
Riviere, Michel, Ecully, FRANCE
PI US 2003133947 A1 20030717
AI US 2002-211502 A1 20020802 (10)
RLI Continuation-in-part of Ser. No. US 2001-784982, filed on 16 Feb 2001, PENDING Division of Ser. No. US 1999-232477, filed on 15 Jan 1999, GRANTED, Pat. No. US 6228846 Continuation-in-part of Ser. No. WO 1997-FR1316, filed on 15 Jul 1997, UNKNOWN
PRAI FR 1996-9401 19960716
DT Utility
FS APPLICATION
LN.CNT 851
INCL INCLM: 424/199.100
INCLS: 424/204.100; 435/006.000; 435/069.100; 435/320.100
NCL NCLM: 424/199.100
NCLS: 424/204.100; 435/006.000; 435/069.100; 435/320.100
IC [7]
ICM: C12Q001-68
ICS: C12P021-06; A61K039-12; C12N015-00; C12N015-09; C12N015-63; C12N015-70; C12N015-74
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 5 OF 13 USPATFULL on STN
AN 2003:23336 USPATFULL
TI Feline polynucleotide vaccine formula
IN Audonnet, Jean-Christophe, Lyon, FRANCE
Bouchardon, Annabelle, Lyon, FRANCE
Baudu, Philippe, Craponne, FRANCE
Riviere, Michel, Ecully, FRANCE
PI US 2003017172 A1 20030123
AI US 2001-943443 A1 20010830 (9)
RLI Division of Ser. No. US 1999-232278, filed on 15 Jan 1999, PATENTED
Continuation-in-part of Ser. No. WO 1997-FR1315, filed on 15 Jul 1997, UNKNOWN
PRAI FR 1996-9337 19960719
DT Utility
FS APPLICATION
LN.CNT 2714
INCL INCLM: 424/202.100
INCLS: 424/093.200; 435/320.100; 424/224.100
NCL NCLM: 424/202.100
NCLS: 424/093.200; 435/320.100; 424/224.100
IC [7]
ICM: A61K048-00
ICS: A61K039-295; A61K039-205; C12N015-86
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 6 OF 13 USPATFULL on STN
AN 2002:122824 USPATFULL
TI Oral immunization with transgenic plants
IN Arntzen, Charles J., Ithaca, NY, United States
Mason, Hugh S., Ithaca, NY, United States
Tariq, Haq A., San Antonio, TX, United States
Clements, John D., New Orleans, LA, United States
PA The Texas A&M University System, College Station, TX, United States (U.S. corporation)
The Administrators of the Tulane Fund, New Orleans, LA, United States (U.S. corporation)
PI US 6395964 B1 20020528
WO 9612801 19960502
AI US 1997-817906 19970804 (8)
WO 1995-US13376 19951024
19970804 PCT 371 date
DT Utility
FS GRANTED
LN.CNT 2920

INCL INCLM: 800/288.000
      INCLS: 424/186.100; 424/257.100; 424/261.100; 435/069.300; 435/320.100;
             435/419.000; 435/468.000; 800/287.000; 800/298.000
NCL   NCLM: 800/288.000
      NCLS: 424/186.100; 424/257.100; 424/261.100; 435/069.300; 435/320.100;
             435/419.000; 435/468.000; 800/287.000; 800/298.000
IC   [7]
      ICM: C12N005-04
      ICS: C12N015-82; C12N015-87; A01H005-00
EXF   800/278; 800/287; 800/288; 800/295; 800/298; 800/FOR101; 800/FOR102;
      424/184.1; 424/185.1; 424/190.1; 424/192.1; 424/197.11; 424/236.1;
      424/241.1; 424/257.1; 424/186.1; 424/261.1; 435/69.3; 435/410; 435/419;
      435/320.1; 435/468; 536/23.1; 536/23.7
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 7 OF 13 USPATFULL on STN
AN   2002:34189 USPATFULL
TI   Feline polynucleotide vaccine formula
IN   Audonnet, Jean-Christophe, Lyons, FRANCE
      Bouchardon, Annabelle, Lyons, FRANCE
      Baudu, Philippe, Craponne, FRANCE
      Riviere, Michel, Ecully, FRANCE
PA   Merial, Lyons, FRANCE (non-U.S. corporation)
PI   US 6348196   B1   20020219
AI   US 1999-232278   19990115 (9)
RLI   Continuation-in-part of Ser. No. WO 1997-FR1315, filed on 15 Jul 1997
PRAI FR 1996-9337   19960719
DT   Utility
FS   GRANTED
LN.CNT 939
INCL INCLM: 424/202.100
      INCLS: 424/204.100; 424/221.100; 435/320.100; 514/044.000
NCL   NCLM: 424/202.100
      NCLS: 424/204.100; 424/221.100; 435/320.100; 514/044.000
IC   [7]
      ICM: A61K039-295
EXF   435/320.1; 514/44; 424/202.1; 424/204.1; 424/207.1; 424/208.1; 424/221.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 8 OF 13 USPATFULL on STN
AN   2001:119336 USPATFULL
TI   Polynucleotide vaccine formula against canine pathologies, in particular
      respiratory and digestive pathologies
IN   Audonnet, Jean-Christophe, Lyon, France
      Bouchardon, Annabelle, Lyon, France
      Riviere, Michel, Ecully, France
PI   US 2001009959   A1   20010726
      US 6586412   B2   20030701
AI   US 2001-784982   A1   20010216 (9)
RLI   Division of Ser. No. US 1999-232477, filed on 15 Jan 1999, GRANTED, Pat.
      No. US 6228846 Continuation-in-part of Ser. No. WO 1997-FR1316, filed on
      15 Jul 1997, UNKNOWN
PRAI FR 1996-9401   19960719
DT   Utility
FS   APPLICATION
LN.CNT 661
INCL INCLM: 536/023.700
      INCLS: 514/044.000; 435/320.100; 424/186.100; 424/190.100; 424/201.100;
             424/224.100; 424/229.100; 424/231.100; 424/248.100; 536/023.100;
             536/023.720; 435/069.100; 435/455.000; 435/466.000; 435/476.000
NCL   NCLM: 514/044.000
      NCLS: 435/320.100; 536/023.700; 536/023.720
IC   [7]
      ICM: A61K048-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 9 OF 13 USPATFULL on STN
AN   2001:67657 USPATFULL